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ARTICLE

OPEN

Host and bacterial proteases inﬂuence bioﬁlm formation and
virulence in a murine model of enterococcal catheterassociated urinary tract infection
Wei Xu1, Ana L. Flores-Mireles1, Zachary T. Cusumano1,2, Enzo Takagi1, Scott J. Hultgren1 and Michael G. Caparon1
Enterococcus faecalis is a leading causative agent of catheter-associated urinary tract infection (CAUTI), the most common hospitalacquired infection. Its ability to grow and form catheter bioﬁlm is dependent upon host ﬁbrinogen (Fg). Examined here are how
bacterial and host proteases interact with Fg and contribute to virulence. Analysis of mutants affecting the two major secreted
proteases of E. faecalis OG1RF (GelE, SprE) revealed that while the loss of either had no effect on virulence in a murine CAUTI model
or for formation of Fg-dependent bioﬁlm in urine, the loss of both resulted in CAUTI attenuation and defective bioﬁlm formation.
GelE−, but not SprE− mutants, lost the ability to degrade Fg in medium, while paradoxically, both could degrade Fg in urine. The
ﬁnding that SprE was activated independently of GelE in urine by a host trypsin-like protease resolved this paradox. Treatment of
catheter-implanted mice with inhibitors of both host-derived and bacterial-derived proteases dramatically reduced catheterinduced inﬂammation, signiﬁcantly inhibited dissemination from bladder to kidney and revealed an essential role for a host
cysteine protease in promoting pathogenesis. These data show that both bacterial and host proteases contribute to CAUTI, that
host proteases promote dissemination and suggest new strategies for therapeutic intervention.
npj Bioﬁlms and Microbiomes (2017)3:28 ; doi:10.1038/s41522-017-0036-z

INTRODUCTION
Catheter-associated infections, particularly catheter-associated
urinary tract infections (CAUTI), are the most common hospital
acquired infections (HAI) worldwide and account for up to 40% of
HAI in the USA.1,2 More than 560,000 patients develop CAUTI each
year, which if untreated can lead to serious complications
including bacteremia and death.3–6 Over the past few decades,
Enterococcus faecalis has emerged as an important cause of CAUTI,
whose treatment options are becoming increasingly limited due
to its resistance to heat and aseptic solutions and its inherent and
acquired resistances to multiple antibiotics, including vancomycin.7,8 Thus, understanding the molecular mechanisms of CAUTI
pathogenesis is a critical need for the development of new
antibiotic-sparing therapies.
One trait that has been established as important for the
pathogenesis of enterococcal HAI and CAUTI is their ability to form
bioﬁlm on urinary catheters and other implantable devices.9
However, we have a relatively incomplete understanding of the
genes and mechanisms used by enterococci to form bioﬁlm in
general and in the urinary tract environment in particular (for
review, see ref. 10). One complication, is that in vitro assays for
analysis of bioﬁlm formation and growth are exquisitely sensitive
to medium conditions and it is not always clear that conditions
established for optimal formation of bioﬁlm in vitro are
representative of the in vivo environment encountered by
enterococci during pathogenesis.10 For example, in the most
widely used in vitro model (TSBG: trypicase soy broth +0.25%
glucose), formation of bioﬁlm structure is dependent on

extracellular DNA (eDNA) released from enterococci by a fratricide
mechanism that requires activation of the endogenous autolysin
Atn in a minor population of cells within the bioﬁlm.11,12 While
deletion of the gene encoding Atn signiﬁcantly reduces bioﬁlm
formation in the TSBG assay,11–13 these mutants are fully virulent
and capable of forming catheter-associated bioﬁlm in vivo in an
optimized murine model of CAUTI,14 suggesting that the TSBG
assay may not represent conditions encountered in CAUTI.
Insight into this discrepancy has come from analysis of the
endocarditis and bioﬁlm-associated (Ebp) pilus, an established
virulence factor in the murine CAUTI model. Ebp has been shown
to contribute to bioﬁlm formation in the TSBG in vitro assay15 and
to the formation of catheter bioﬁlm in vivo in murine CAUTI.16–18
However, it has mechanistically different roles in each habitat. For
the TSBG assay, Ebp promotes attachment of E. faecalis directly to
several abiotic materials, including PVC, polystyrene, and silicone.15,16 In contrast, Ebp cannot promote attachment to abiotic
substrates, including silicone catheter material, when exposed to
urine, despite its role as a critical determinant for the attachment
of E. faecalis to the catheter following its implantation into the
murine bladder.16 This paradox was resolved when it was found
that the catheter elicits an inﬂammatory response resulting in the
release of the host protein ﬁbrinogen (Fg) into the bladder lumen
which coats the catheter.16 The pilus is tipped with the Fg-binding
adhesin, EbpA, which binds to the Fg-coated catheter to initiate
bioﬁlm formation.16 Analysis of human urinary catheters supports
a similar mechanism of Fg-mediated pathogenesis in human
CAUTI19 and therapies that can block EbpA-Fg interaction are
effective for both prophylaxis and treatment of CAUTI in the
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RESULTS
Enterococcal secreted proteases are required for optimum
virulence in a murine model of CAUTI
Most strains of E. faecalis, including the well-characterized strain
OG1RF and the prototype vancomycin-resistant (VRE) strain V583,
express two secreted proteases, the metalloproteinase gelatinase
(GelE) and a serine protease (SprE).24 The genes for both are cotranscribed from the same operon whose expression is under the
control of the Fsr-quorum sensing system.25,26 To construct
mutants deﬁcient for expression of a single protease, in-frame
npj Biofilms and Microbiomes (2017) 28

deletion mutants were constructed in OG1RF that individually
lacked gelE (ΔGelE) or sprE (ΔSprE), as well as a mutant that lacked
expression of both proteases (ΔGS). All mutants had growth rates
identical to the WT strain when examined in a standard rich
medium (BHI, data not shown). The virulence of this panel of
strains was then compared in our well-established murine model
of CAUTI, which involves transurethral injection of bacteria into
mice whose bladders have been implanted with a segment of
silicone catheter.14 Virulence is quantitated by determination of
the number of CFUs recovered from catheters, bladders and
kidneys following 24 h of infection.14 This analysis revealed that
the loss of an individual protease did not signiﬁcantly alter
colonization as compared to wild type (WT) with regards to CFUs
recovered from the catheter (Fig. 1a), bladder (Fig. 1b) or kidney
(Fig. 1c). In contrast, the mutant that lacked both proteases was
signiﬁcantly attenuated, with the number of CFUs recovered
reduced by more than 1 log in all three compartments (ΔGS,
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murine model.16,20 Taken together, these differences in the
mechanism of Ebp-mediated bioﬁlm among different habitats
are mostly dependent on host and environmental factors and not
the composition of the abiotic bioﬁlm substratum.
These differences in host and environmental factors that affect
bioﬁlm formation in urine have been examined in greater detail,
with the goal of developing an in vitro model that more accurately
mimics CAUTI bioﬁlm formation. While some E. faecalis strains
have been reported to grow in urine,21 others grow very poorly
and in all cases the efﬁciency of growth of any strain can be highly
sensitive to the urine donor(s) (W. Xu, A. Flores-Mireles, S. Hultgren
and M. Caparon, unpublished observations; M. S. Gilmore,
personal communication). For example, the well-characterized E.
faecalis strain OG1RF typically grows very poorly in urine in vitro,
even though it is highly proﬁcient in causing CAUTI in the murine
model, with infection characterized by high overall bacterial
burdens in the bladder and robust catheter-associated bioﬁlm.16
However, if Fg is added to urine to mimic conditions encountered
in the catheterized bladder, E. faecalis OG1RF grows several logs
over the original inoculum, consumes Fg and forms bioﬁlm on
silicone catheters.16 Supplementation with BSA or casamino acids
could also support growth, but only Fg was capable of promoting
bioﬁlm formation. Also, similar to bioﬁlm formation in CAUTI,
bioﬁlm formed in Fg-urine is dependent on the Fg-binding activity
of EbpA.16 These data show that a source of peptides can enhance
growth in urine and that not only does Fg provide a critical
substrate for attachment, that it can also serve as a key nutrient to
support the growth of E. faecalis bioﬁlm in the catheterized
bladder.
The molecular details of how E. faecalis processes Fg and the
biochemical pathways by which Fg supports growth are unknown.
A complication is that Fg is a large glycoprotein (340 kDa),
composed of three pairs of non-identical polypeptide chains: Aαchain (610 amino acids, ~67 kDa), Bβ-chain (461 amino acids, ~55
kDa) and γ-chain (411 amino acids, ~48 kDa).22 For catabolism,
bacterial generally lack the capacity to transport large polypeptides across their cellular membranes. Instead, they rely on
secreted proteases to process large polypeptides into short
peptides in the extracellular space that can then be transported
into their cytoplasmic compartments by dedicated oligopeptide
permeases.23 This suggests that the ability of E. faecalis to
consume Fg as a growth substrate will be dependent on secreted
proteases.
In this work, we examined the role of secreted proteases in the
ability of E. faecalis to grow and form bioﬁlm in an optimized
model of CAUTI bioﬁlm in vitro and for bioﬁlm formation and
pathogenesis in a murine model of CAUTI. Through analysis of
mutant enterococcal strains defective in expression of several
secreted proteases and through chemical inhibition of proteases
we show that both bacterial and host proteases contribute to the
ability of enterococci to utilize Fg during CAUTI and that host
proteases play a major role in promoting inﬂammation and
dissemination. Together, these data suggest that targeted
inhibition of proteases can be developed into new antibioticsparing therapies for treatment of CAUTI.
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Fig. 1 GelE and SprE are functionally redundant in CAUTI. Catheterimplanted mice were infected with ~2 × 107 CFU of the indicated
strains (see Table S1). Following 24 hrs of infection, total numbers of
CFU recovered were determined for a Catheter, b Bladder and c
Kidney. Each symbol represents an individual mouse and symbols
touching the dashed lines indicate values below the limit of
detection (LOD, 40 CFU). Data shown are pooled from two
independent experiments. For each strain, the mean value is shown
as the horizontal line. *p < 0.05, **p < 0.005, ***p < 0.001
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mutant that expressed only SprE lacked all activity (ΔGelE, Fig. 2d).
However, when grown in urine, both single mutants (ΔGelE,
ΔSprE) had detectable protease activity. Activity was reduced as
compared to WT (Fig. 2d) and in contrast to BHI medium, the
mutant that only expressed SprE had detectable activity that was
equivalent to ~40% of WT (ΔGelE, Fig. 2e). This activity was due to
SprE, as deletion of the genes for both proteases reduced activity
to that of urine alone (ΔGS, Fig. 2e). This latter activity was
at a low, but detectable level (~3% of WT) suggesting urine has a
low residual protease activity (Medium, Fig. 2e). As expected,
expression of deleted genes in each respective mutant complemented mutant phenotypes in both BHI and urine (Fig. S1). These
data show that unlike standard culture conditions, SprE contributes to proteolytic activity under conditions more representative of the urinary tract (UT) environment.

Figs. 1a–c). Taken together, these data indicate that protease
expression is required for optimum virulence in CAUTI, but that
GelE and SprE are functionally redundant.
Expression of both proteases is upregulated in human urine
To date, SprE has not been associated with virulence in other
models of enterococcal infection. To gain insight into how SprE
can promote virulence in CAUTI, the relative expression of each
protease was examined following growth in BHI or in human
urine. The expression of each protease was then quantitated by
determination of protease activity in cell-free supernatants and by
real time RT-PCR. Using a standard FITC-casein substrate, analysis
of proteolytic activity revealed that overall caseinolytic activity was
stimulated ~7 fold following growth in human urine vs. growth in
BHI (Fig. 2a). Associated with this, expression of sprE and gelE was
50–100 fold higher in urine than in BHI (Fig. 2b). Expression of fsrA
and fsrB was also ~100-fold elevated in urine and no protease
activity was detected in a mutant with an in-frame deletion in fsrB
during growth in urine (data not shown). These data show that the
urinary tract environment is optimal for expression of both
proteases and that their elevated expression in urine is dependent
on the Fsr quorum-sensing system.
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SprE has proteolytic activity in urine but not in rich medium
Expression of GelE, but not SprE, correlated with protease activity
on protease indicator plates, as ΔSprE (which expresses GelE) had
caseinolytic activity equivalent to WT, while the mutants that
lacked GelE (ΔGelE, ΔGS) lost all detectable activity (Fig. 2c). A
similar pattern was observed following growth in BHI medium, as
only cell-free supernatants from GelE−expressing stains (WT,
ΔSprE) had activity against a FITC-casein substrate, while the

Relative Protease Activity

In urine SprE can be activated by a GelE− independent mechanism
Under standard growth conditions in BHI, the processing of the
SprE zymogen to the active enzyme requires the protease activity
of GelE.27 The observation above shows that SprE is active in urine
in the absence of GelE, suggesting an alternative activation
mechanism in this environment. To test this hypothesis, an
epitope-tagged version of SprE was constructed and expressed
from a plasmid in various mutants to derive GelE+ and GelE−
backgrounds. The processing of SprE was then monitored in
immunoblots. Tagged SprE retained proteolytic activity (Fig. S1)
and processing correlated with the appearance of a SprE
polypeptide that was approx. four KiloDalton smaller that inactive
SprE in immunoblots (Fig. S2). Following culture in BHI, the smaller
active-associated form of SprE was only observed in culture
supernatants from GelE+ strains and was not observed in GelE−

400
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BHI
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***

***

WT ΔGelE ΔSprE ΔGS Medium

Fig. 2 ΔGelE has protease activity in urine, but not BHI. Expression of protease activity against a FITC-casein substrate a and relative
transcription of the genes encoding the E. faecalis secreted proteases from the WT strain, as determined by real time RT-PCR b were assessed
following 24 h of culture in the indicated medium. Protease activity of various strains (see Table S1) on protease indicator plates c and in
supernatants from strains grown in BHI d or urine e following overnight culture. Values are normalized vs. culture density (OD600) and are
compared to BHI a, b or compared to uninoculated media (Medium; d, e). On indicator plates, protease activity is apparent as a zone of
clearing around the bacterial growth. Data are derived from a minimum of three independent experiments are shown as the mean ± SEM. For
the indicated pair-wise comparisons, ***p < 0.001
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Fig. 3 GelE-independent activation of SprE in urine. a GelE− and GelE+ strains expressing SprE were constructed by complementing the
indicated mutants with a plasmid expressing HA-tagged SprE (pSprE) or GelE and HA-tagged SprE (pGS). Supernatants (super) and cell lysates
(cell) were then prepared following overnight culture in the indicated medium and subjected to a Western blot analysis to detect HA-tagged
SprE. Arrows at the right indicate pro-SprE (closed) and mature SprE (open). Migration of several molecular weight standards are shown on the
left. All blots are derived from the same experiment and processed in parallel. b Morphology of WT and ΔGS strains following overnight
growth in the indicated medium was determined by phase contrast microscopy following ﬁxation

backgrounds (Fig. 3a). In contrast, following growth in urine, the
smaller SprE band was now present in both GelE+ and GelE−
backgrounds (Fig. 3a). The loss of GelE activity has been associated
with increased chain lengths, possibly through activation of a
muramidase.28 Consistent with this, the loss of GelE, but not SprE,
was associated with the formation of long multi-cellular chains of
10–15 cells following culture in BHI (Fig. 3b). The loss of both GelE
and SprE lead to longer chains during growth in urine, although
not to the same extend as in BHI medium, likely because of more
limited growth (Fig. 3b). These observations suggest that while
maturation of active SprE in BHI medium requires GelE, that the
SprE zymogen can be activated independently from GelE in urine.
Enterococcal secreted proteases are required for processing Fg
Since Fg can promote the growth of E. faecalis OG1RF in urine
in vitro, we examined whether the enterococcal-secreted proteases had the ability to cleave Fg. When examined following
growth in BHI, supernatants from the WT strain cleaved Fg,
preferentially making an initial cleavage in the Fg Aα, followed by
cleavage in the Bβ and γ chains (Fig. 4a). Similar to caseinolytic
activity, those mutants that lacked GelE lost the ability to process
Fg into smaller peptides following growth in BHI (ΔGelE, ΔGS;
Fig. 4a), while processing was indistinguishable from WT in the
mutant lacking expression of SprE (ΔSprE, Fig. 4a). In contrast,
when this same panel of mutants was grown in urine, the mutant
that lacked both proteases could not cleave Fg, even after 6 h of
incubation (ΔGS, Fig. 4b), while the mutant that only expressed
SprE was able to cleave Fg, although not as efﬁciently as WT
(ΔGelE, Fig. 4b). Upon extended incubation (48 h), no additional
cleavage of Fg was observed in supernatants from BHI grown
cultures or from incubation of Fg in uninoculated BHI (Fig. 4a).
However, at this time point, Fg was cleaved upon exposure to
normal urine alone, suggesting normal urine has protease activity
against Fg (Fig. 4b). To gain insight into this protease activity,
urines were supplemented with various inhibitors of the major
classes of proteases. Only inhibitors of serine proteases, including
trypsin inhibitor, could inhibit Fg cleavage (Table S3). Taken
npj Biofilms and Microbiomes (2017) 28

together, these data show that: i) the enterococcal secreted
proteases are required for processing Fg; ii) while GelE is the
dominant protease responsible for processing in a standard
medium, both GelE and SprE contribute to processing in
conditions more representative of the bladder ecology and; iii)
there is a low level of a trypsin-like protease activity present in
normal urine.

Enterococcal proteases promote cellular association of Fg
cleavage products
To examine the fate of the cleavage products of Fg, we developed
an assay to detect the association of Fg with enterococcal cells.
Since pigments in BHI were autoﬂuorescent, this assay employed
an optimized M9 minimal salt-based medium (“optimized M9,” see
Materials and Methods). In this assay, ﬂuorescently-labeled Fg (Fgalexa ﬂuor 488 conjugate) was added to optimized M9 or urine,
which were then inoculated with various E. faecalis strains and
cultured overnight. Aliquots were removed and the cellular
association with Fg was assessed by ﬂow cytometry. This assay
revealed that following incubation in optimized M9, the WT strain
demonstrated an ability to associate with the labeled Fg (WT,
Fig. 4c), although this ability was lost if cells were washed in PBS
prior to the addition of Fg (WT PBS, Fig. 4c). The ability of the Fg to
associate with cells was dependent on the expression of GelE, as
mutants that lacked GelE activity (ΔGelE, ΔGS) had an approximately 10-fold lower ability to associate with Fg, and the mutant
that only expressed SprE lacked the ability to associate with Fg
(ΔGelE, Fig. 4c). In contrast, following growth in urine, mutants
that expressed either GelE or SprE demonstrated an ability to
associate with Fg, as compared to the mutant that lacked both
proteases (ΔGS, Fig. 4d). For cellular association, these data show
that consistent with Fg processing behavior, GelE is required in
artiﬁcial medium, but that GelE and SprE are functionally
redundant under conditions more representative of the bladder
environment.
Published in partnership with Nanyang Technological University

Catheter-associated urinary tract infection
W Xu et al.

5

S
G

U
ri
ne

rE
Sp

G

W

BH

G

T

b

I

S

rE
Sp

W

kDa
60

G

T

el
E

a

el
E

reproduced with optimized M9 medium (Fig. 4e). In contrast,
supplementing optimized M9 with Fg, bovine serum albumin
(BSA) or casamino acids all enhanced growth yields by over 1 log
(Fig. 4e). A similar result was observed for supplementation of
urine with Fg or BSA (Fig. 4f). In optimized M9, the ability of Fg or
BSA to enhance growth was dependent on GelE, as enhanced

Host and enterococcal proteases promote Fg-dependent growth
The contribution of secreted proteases to the ability of Fg to
enhance enterococcal growth was then examined. Consistent with
prior results,16 E. faecalis OG1RF had a limited ability to grow in
normal human urine, with a growth yield typically less than a 1 log
increase over the initial inoculum (2 × 106 cells/ml), which was
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Fig. 4 In urine GelE and SprE are functionally redundant for processing Fg and can enhance Fg-dependent bioﬁlm formation. The ability of
supernatants derived from the indicated strains (see Table S1) to process Fg is shown following overnight culture in BHI a or urine b. Cell-free
supernatants were prepared, Fg was added and after an additional 6 or 48 h of incubation, the resulting cleavage patterns were resolved by
SDS-PAGE and staining with Coomasie Brilliant blue for comparison to Fg incubated in uninoculated BHI (BHI) or urine (Urine). Migration of the
Aα, Bβ, and γ chains of Fg and of several molecular weight standards are shown the right and left, respectively. All blots are derived from the
same experiment and processed in parallel. The ability of alexa-ﬂuor Fg to associate with the cell surface of the indicated strains following
growth in optimized M9 medium c or urine d was analyzed by FACS. Enterococcal cells were counter stained with SYTO59. A PBS-washed WT
and a SYTO59-only WT were used as control. Numbers in each panel indicates the percentage of the total number of cells contained within
the indicated quadrant. The ability of the supplements indicated at the right to enhance growth in optimized M9 medium e or urine f was
assessed by growth following overnight incubation by determination of CFUs. The ability of secreted proteases to enhance bioﬁlm formation
in the absence (unsupp.) or presence of Fg (+Fg) in TSBG g or urine h is shown. Bioﬁlm formation by the indicated strains was analyzed
following 48 h of incubation in 96-well plates by absorbance (A595) following staining with Crystal Violet. Bioﬁlm was normalized with growth
density measured at OD600. Data shown are from a minimum of three independent experiments and are shown as the mean ± SEM. For the
indicated pair-wise comparisons, *p < 0.05, **p < 0.005, ***p < 0.001, ns not signiﬁcant

growth was not observed for mutants lacking GelE (ΔGelE, ΔGS).
Casamino acids enhanced growth (a source of amino acids and
small peptides derived from hydrolysis of casein) independent of
GelE (Fig. 4e), indicating that the proteolytic activity of GelE was
required to process Fg and BSA into smaller peptides that could
then be metabolized. In contrast, in urine, Fg or BSA could
enhance growth of the mutant lacking either GelE or SprE (ΔGS,
Fig. 4f), indicating that host proteolytic activity present in normal
urine can sufﬁciently process Fg or BSA to promote enterococcal
growth.
Both SprE and GelE are required for optimal bioﬁlm formation in
Fg-urine
Next, we compared the panel of protease mutants for their ability
to form bioﬁlm in the standard TSBG and in the optimized Fgurine assay. In TSBG, the WT formed a thick bioﬁlm and the loss of
GelE but not SprE, resulted in signiﬁcantly less bioﬁlm formation
(compare ΔGelE, ΔGS to ΔSprE, Fig. 4g). In contrast, no strain was
able to form appreciable levels of bioﬁlm in the presence of urine
(Fig. 4h). However, the addition of Fg enhanced bioﬁlm formation
of the WT strain in both TSBG (~2 fold, Fig. 4g) and in urine (~6
fold, Fig. 4h). In TSBG, the ability of Fg to enhance bioﬁlm was
dependent on GelE but not SprE, as mutants lacking the former
demonstrated no increase in bioﬁlm formation in the presence of
Fg, while the mutant in the latter was indistinguishable from WT
(ΔGelE and ΔGS vs. ΔSprE, Fig. 4g). Unlike the TSBG, the loss of
either GelE or SprE did not alter bioﬁlm formation in Fg-urine
relative to WT (ΔGelE, ΔSprE, Fig. 4h). However, the loss of both
resulted in signiﬁcantly less bioﬁlm formation in Fg-urine (ΔGS,
Fig. 4h). The loss of both secreted proteases did not reduce bioﬁlm
formation in Fg-urine to the levels observed in the absence of Fg
(ΔGS, Fig. 4h), consistent with the ability of normal urine to
promote growth in Fg-urine as described above. Taken together,
these data show that secreted proteases are important for the
formation of Fg-enhanced bioﬁlm and the combination of
protease activity and Fg enhance bioﬁlm formation to a much
greater extend in urine than in TSBG. Furthermore, while GelE is
the major protease required for Fg-enhanced bioﬁlm formation in
TSBG, host proteases may contribute to Fg-dependent bioﬁlm
formation in urine. However, the enterococcal-secreted proteases
are required for optimal bioﬁlm formation in Fg-urine, although
unlike Fg-TSBG, GelE, and SprE are functionally redundant in the
Fg-urine assay.
Chemical inhibition of proteases improves outcome in murine
CAUTI
Since the data presented above show that secreted enterococcal
proteases enhance CAUTI pathogenesis, we investigated whether
treatment with several commonly used protease inhibitors could
alter the course of pathogenesis in the murine CAUTI model. A
commercially available protease inhibitor cocktail (cOmplete™,
npj Biofilms and Microbiomes (2017) 28

Mini, Roche) was effective at inhibiting caseinolytic activity from
both host and bacterial proteases during growth in vitro in urine
(Fig. 5a) and for inhibiting the ability of Fg- or BSA to enhance
enterococcal growth in urine (Fig. 5b). Groups of C57BL/6NCI mice
received a range of doses of the cocktail (0, 20, 100, and 500 mg/
kg/day) delivered intraperitoneally according the schedule
described in Fig. 5c. Urines were collected following 12 and 24 h
(Fig. 5c) and tested for inhibitory activity by adding Fg, incubating
the mixture overnight and assessing the cleavage of Fg by SDSPAGE. This analysis revealed that the highest dose (500 mg/kg/
day) had a detectable ability to block Fg degradation by host
proteases after one injection (12 h, Fig. 5d), while inhibitory
activity was detectable by the lowest dose tested after two
injections (20 mg/kg/day, Fig. 5d), indicating the presence of
therapeutic concentrations of the inhibitors. Following the second
dose at 24 h, mice were implanted with catheters and infected
and then received additional doses of the cocktail every 12 h over
the course of a 72 h experiment (Fig. 5c). At this point, bacterial
burdens on catheter, bladder and kidney were evaluated by
determination of recoverable CFU. This analysis revealed that
burdens were; i) signiﬁcantly reduced as compared to vehicle
(PBS) on catheters at the highest dose (500 mg/kg/day, Fig. 5e); ii)
signiﬁcantly reduced at the two highest doses in bladder (100,
500 mg/kg/day; Fig. 5f) and; iii) reduced at all doses in kidney (20,
100, 500 mg/kg/day; Fig. 5g). Most strikingly, protease inhibitor
treatment not only reduced bacterial burdens in kidneys, but
signiﬁcantly blocked dissemination to kidneys, as deﬁned by
reducing recoverable CFU to below the limit of detection (LOD,
Fig. 5g).
Inhibition of host cysteine protease activity alters pathogenesis in
CAUTI
Since the inhibitor cocktail targets multiple classes of proteases,
we next examined the effect of inhibitors targeting speciﬁc classes
of proteases. Well-characterized non-toxic inhibitors targeting
serine proteases (Pefabloc), metalloproteases (EDTA), cysteine
proteases (E64), and a mixture (Pefaloc + EDTA +E64) were used to
treat infected mice as described above (Fig. 5c). While the various
treatments did not alter the numbers of recoverable CFUs on
catheters as compared to mock (PBS) treated mice (Fig. 6a),
bacterial burdens were signiﬁcantly reduced in bladders by
Pefabloc and EDTA (Fig. 6b). Most strikingly, bacterial burdens in
kidney were signiﬁcantly reduced by the combination of Pefabloc,
EDTA, and E64 (“mixed”) and by E64 alone (Fig. 6c). This indicates
that E64 was sufﬁcient to decrease dissemination. To examine this
latter effect in greater detail, the histology of E64-treated bladders
was examined following 48 h of infection. While un-catheterized
and uninfected bladders showed the characteristic folds of
urothelium projecting into the lumen (Naïve, Fig. 6d), bladders
that were implanted with catheters, but were not infected, were
inﬂamed as previously described7,14,16 with an edematous lamina
Published in partnership with Nanyang Technological University
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Fig. 5 Protease inhibitor treatment reduced bacterial burden in CAUTI. a The ability of a protease inhibitor cocktail (cOmplete™ Mini) to
inhibit E. faecalis protease activity was assessed following overnight growth of the indicated strains in urine. Protease activity in supernatants
against a FITC-casein substrate was then determined. b The growth of the WT strain in urine unsupplemented (unsupp.) or supplemented as
indicated, in the presence or absence of the inhibitor cocktail was assessed by determination of CFUs following overnight growth. c
Experimental timeline for treatment of murine CAUTI. The inhibitor cocktail was administered by intraperitoneal injection (dose) in four
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propria that has expanded to occlude much of the lumen (Mock,
Fig. 6e). Numerous studies have shown that infection of catheterimplanted bladders by E. faecalis typically does not produce
further alterations to bladder tissue architecture.7,14,16,29 However,
infected catheter-implanted bladders treated with E64 have a
markedly different appearance. These bladders appeared distended with markedly reduced edema of the lamina propria
(Fig. 6f) and this was consistently observed for all bladders
examined (N = 8, Fig. S3). Given that the genome of E. faecalis
OG1RF does not encode any apparent cysteine protease that can
Published in partnership with Nanyang Technological University

be targeted by E64,30 this result suggests that inhibition of a host
cysteine protease can inﬂuence the pathogenesis of CAUTI.
DISCUSSION
Using a combination of mutants and chemical inhibition, we show
that both enterococcal and host proteases contribute to the
pathogenesis of E. faecalis CAUTI. The enterococcal secreted
proteases were required for growth and bioﬁlm formation in Fgsupplemented urine, a condition more representative of the CAUTI
npj Biofilms and Microbiomes (2017) 28
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habitat than traditional in vitro assay conditions. The enterococcal
proteases were also required for bioﬁlm formation and virulence
in a murine model of CAUTI. Furthermore, a host cysteine protease
promotes inﬂammation in the catheterized bladder that facilitates
dissemination of the infection to the kidney. These data suggest
that a strategy targeting inhibition of speciﬁc proteases can be
developed to augment existing therapies against CAUTI and
disseminated infection. This approach will likely prove efﬁcacious
against other pathogens, including Staphylococcus aureus and
Candida albicans, that are also known to exploit Fg for CAUTI
pathogenesis.19
This study contributes to our understanding of the important
role of Fg in catheter-bioﬁlm formation in promoting both
enhanced growth in urine and better bioﬁlm. Several unexpected
results, including that: (i) GelE and SprE are functionally redundant
for CAUTI pathogenesis; (ii) there is a GelE-independent pathway
for activation of SprE in the urinary tract and; (iii) SprE can support
CAUTI pathogenesis independent of GelE. Traditionally, GelE has
been recognized as the secreted protease that plays a major role
in the pathogenesis of multiple enterococcal diseases, including
peritonitis and endocarditis.28,31–33 There is considerably less
information on the possible contribution of SprE to pathogenesis.
Its best-characterized role is in eDNA-dependent bioﬁlm formation, where it can modulate the amount of cell lysis by modifying
AltA autolysin against further proteolytic activation by GelE.31
However, consistent with the data presented here, a requirement
for GelE to activate SprE under most in vitro conditions,27 means
that the loss of GelE is epistatic on SprE activity. Thus, a GelE
mutant will lack both GelE and SprE activities, making it difﬁcult to
parse out SprE’s speciﬁc contributions. A different situation was
observed in urine, as a host protease could activate SprE
independently of GelE. The fact that both proteases had activity
against Fg can explain why they were functionally redundant in
urine and that the loss of both was required for attenuation in
CAUTI, consistent with our prior observation that disruption of
GelE alone did not result in reduced virulence in CAUTI.14
The presence of a host protease with activity against Fg can also
explain why the ΔGS mutant had enhanced growth in Fg-urine
npj Biofilms and Microbiomes (2017) 28

in vitro, despite its lack of both GelE and SprE. This observation is
consistent with a prior study that reported a proteolytic activity in
normal urine active against albumin.34 Consistent with this, a
proteomic comparison of proteins associated with an implanted
catheter between uninfected and infected mice, revealed that the
precursor of the serine protease trypsin was associated with
catheters recovered from uninfected mice (Table S4), suggesting
that the SprE-activating activity in urine was possibly due to
trypsin. Consistent with this, trypsin can activate SprE in vitro
(Fig. S4). However, the situation is likely to be more complicated
during CAUTI vs. normal urine, as: (i) the levels of the trypsin
precursor were decreased below the limit of detection after
24 h of infection and; (ii) infection resulted in the accumulation of
several trypsin/serine protease inhibitors on the catheter
(Table S4). A possible source of these inhibitors may be the
PMN’s recruited into the bladder during CAUTI.7 These infectioninduced changes could affect the dynamics of host and bacterial
protease interaction during CAUTI and may explain why host
protease activity could activate SprE, but not support the
pathogenesis of the ΔGS mutant during CAUTI. Further analysis
will be required to understand how host and enterococcal
proteases and their inhibitors interact during CAUTI.
The functional redundancy of GelE and SprE also raises some
interesting questions about the role of the enterococcal-secreted
proteases in CAUTI pathogenesis. For example, it is not clear why
there is selection to maintain both proteases, when either one is
sufﬁcient to support CAUTI. A broad substrate speciﬁcity for GelE
has been described, including degrading insulin β-chain, bradykinin, and the antimicrobial peptide LL-37.35–37 The substrates of
SprE have not been as well deﬁned, although the data here show
that both SprE and GelE can cleave Fg. Similar to a cysteine
protease (SpeB) in Streptococcus pyogenes and a metalloprotease
(PrtV) in Vibrio cholerae,38,39 the present study shows that E.
faecalis preferentially makes an initial cleavage in the Fg Aα-chain
followed latter by cleavage in the Bβ and γ chains. However, at the
earlier time points in urine, the cleavage patterns between WT,
ΔGelE, and ΔSprE are not identical, suggesting that optimal
processing of Fg requires a synergistic interaction of the two
Published in partnership with Nanyang Technological University
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secreted proteases. In addition, the cleavage patterns of all strains
are different between BHI and urine grown cultures, suggesting
that a host protease also contributes to Fg processing in this
environment.
Our studies using chemical inhibitors of protease activity
implicated the contribution of a host cysteine protease to
pathogenesis that functioned to promote dissemination of the
infection to the kidney. This is consistent with reports that host
proteases can profoundly inﬂuence pathogenesis, including both
anti-inﬂammatory and pro-inﬂammatory effects.40 For example,
GelE may have an anti-inﬂammatory activity by virtue of its ability
to degrade the C3 component of complement.41 Excessive
proteolytic activity can lead to maladaptive host responses and
excess tissue inﬂammation and damage. Several classes of host
cysteine proteases, including caspases, cathepsins and calpains,
have well characterized regulatory roles in the pro-inﬂammatory
response. A common theme involves the proteolytic activation of
pro-inﬂammatory cytokines. For a few examples, danger signals
that activate the inﬂammasome lead to the caspase-family
dependent activation of IL-1β and other cytokines,42 while
calpain-family proteases participate in the inﬂammasomeindependent activation of IL-1α.43 Of interest, IL-1β and IL-1α
can play distinct roles in inﬂammation, with the former more
important for infection, while the latter is more important for
sterile inﬂammation (for review, see ref. 44), similar to what may
be induced during placement of a catheter. Prior results indicate
that IL-1β is upregulated when catheter-implanted bladders are
infected by E. faecalis,14 although the mechanisms responsible for
catheter-induced inﬂammation in the absence of infection have
not been as well characterized.7 However, our observation that
dissemination and inﬂammation are reduced by inhibition of a
host cysteine protease implicates inﬂammation in the control of
dissemination and that this cysteine protease regulates this
response. Optimization of protease-inhibitor therapy will require
the identiﬁcation of this regulatory cysteine protease so that it can
be targeted by more speciﬁc inhibitors.
Protease inhibitor therapies have proven successful for treatment of a constantly expanding list of diverse infectious diseases.
For example, a cysteine protease inhibitor (K11777) rescued mice
from lethal infections by Cryptosporidium parvum, a protozoan
parasite causing stunted infant growth and lethality in immunocompromised individuals.45 Nine protease inhibitors targeting
pathogen proteases have been approved for clinical use against
HIV46 and inhibitors of viral proteases have been successful in
eradicating infection by Hepatitis C virus.47 Therapy directed
against host proteases have also shown efﬁcacy as a serine
protease inhibitor (serpinb1) acted to restore tissue homeostasis
by regulating the innate immune response to protect lungs from
damage by infection with Pseudomonas aeruginosa in a murine
model.48 Interestingly, mutants of E. faecalis lacking the intramembrane protease Eep also showed reduced kidney dissemination in the murine CAUTI model.49 This protease is involved in
maturation of an enterococcal pheromone (cCF10) involved in
cell-to-cell communication and DNA transfer and its activity is
sensitive to chemical inhibition.50 This suggests that by expanding
the repertory of targeted proteases from the secreted proteases to
include various cell-associated proteases, the efﬁcacy of protease
inhibitor therapy in CAUTI can be improved.
Short-term urinary catheterization increases the risk of developing a UTI and other complications up to 80%, and prolonged
catheterization can increase the risk to 100%.51–53 The commensal
Gram-positive bacterium E. faecalis has a remarkable ability to
adapt to the UTI environment by forming bioﬁlm on catheters,
which provides it with a conduit for ascension through the
catheter lumen into the bladder.7 Bioﬁlms can be particularly
challenging from an infection control standpoint, as they are often
refractory to antibiotics and the host immune system. In prior
work we have shown that Fg plays a critical role in catheter bioﬁlm
Published in partnership with Nanyang Technological University

formation by virtue of its ability to coat catheter surfaces.19,20
Since completely blocking Fg deposition on catheters is likely to
prove challenging, we have instead focused on developing
therapies to block enterococci from binding to Fg.16,20 In this
study, we capitalized on the prior observation that Fg can enhance
growth under conditions representative of CAUTI environment,16
and the observation made here that expression of the secreted
proteases GelE and SprE are highly up-regulated upon exposure to
Fg-urine to examine how Fg is processed by these proteases to
enhance bioﬁlm formation and growth. Taken together, these
ﬁndings will guide the development of new therapies that will
improve the efﬁcacies of current treatments and provide a
platform to study the role of the inﬂammatory response in CAUTI.
METHODS
Bacterial strains, media, and growth conditions
Molecular cloning experiments utilized Escherichia coli TOP10 cultured in
Luria–Bertani medium. Experiments involving E. faecalis used strain OG1RF
and several mutant derivatives (see below and Table S1) that were
regularly maintained on Brain Heart Infusion (BD, Franklin Lakes, NJ) (BHI)
agar plates supplemented with 25 μg/ml of rifampin and 25 μg/ml of
fusidic acid.54,55 Liquid media included BHI, Trypticase Soy Broth (BD) +
0.25% glucose (TSBG), human urine (see below), or optimized M9 medium
(see below). Where indicated, liquid media were supplemented with Fg
(Sigma-Aldrich, St. Louis, MO), BSA (Sigma-Aldrich), or Casamino Acids (BD)
by the addition of lyophilized powder directly to media to achieve a ﬁnal
concentration of 1 mg/ml. Unless otherwise speciﬁed, cultures in liquid
media were inoculated from a single colony and grown statically at 37 °C
for 18 h. Bacterial titers were determined as previously described.16 Where
appropriate, antibiotics were added at the following concentrations: E.
faecalis: erythromycin, 30 μg/ml; kanamycin 500 μg/ml; and chloramphenicol 10 μg/ml. E. coli: erythromycin, 500 μg/ml; kanamycin, 50 μg/ml; and
chloramphenicol 10 μg/ml.

Construction of in-frame deletion mutants and complementation
The gelE deletion mutant described previously12 is referred to in this study
as ΔGelE (Table S1). In-frame deletion mutations in other genes were
generated by allelic replacement using a standard method.18 Brieﬂy, the
upstream and downstream sequences ﬂanking the open reading frame of
interest were ampliﬁed by PCR using the oligonucleotide primers listed in
Table S2 and inserted into the allelic replacement vector pGCP213 through
overlap extension PCR.56 The resulting plasmids were the introduced into
the relevant OG1RF host and allelic replacement conducted as described.18
Where indicated, full length open reading frames of gelE, sprE, and gelEsprE were fused with a C-terminal HA tag into the E. coli/E. faecalis shuttle
vector pABG5 as previously described.57 These constructs (Table S1) were
transformed into the corresponding protease deletion mutants for
phenotypic characterization (see below). The ﬁdelity of all constructs and
mutant chromosomes was conﬁrmed by DNA sequence analysis (Genewiz,
South Plainﬁeld, NJ) of PCR products generated using the relevant primers
(Table S2).

Collection of urine
To minimize inﬂuence of donor variability, human urine was collected and
pooled from three healthy female donors between 20–35 years of age,
who have no history of kidney disease, a current UTI, diabetes or were
currently undergoing antibiotic treatment. Urine was sterilized by ﬁltration
through a 0.22 μm ﬁlter (EMD, Milipore) and adjusted to pH 6.0–6.5 prior to
use. All participants have signed an informed consent and the forms are in
compliance with local conﬁdentiality laws. Where indicated, urine was
mimicked using M9 medium (BD) supplemented with 0.04% (wt/vol)
glucose, 9.3 mg/ml urea, 0.6 mg/ml creatinine, 1.29 mg/ml Na3C6H5O7, 2
mM MgSO4, 0.1 mM CaCl2 and 0.005–0.03% yeast extract,58 referred to as
“optimized M9 medium.”

Protease expression and activity
The ability of strains to express protease activity were assessed following
growth on protease indicator plates59,60 and from the supernatants of
liquid cultures using an FITC-casein substrate, normalized to culture
density (OD600), was determined as described.61 The ability of the various
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strains to express HA-tagged protease polypeptides was conducted by
subjecting culture supernatants that were clariﬁed by centrifugation and
ﬁlter-sterilized to a Western blot analysis using a mouse monoclonal antiHA antibody (Sigma-Aldrich, H3663, dilution 1:2000) that was detected
using a goat anti-mouse IgG conjugated with HRP (Sigma-Aldrich, A4416,
1:2000). Blots were developed and imaged using a ChemiDoc PM system
(Bio-Rad), as previously described.62 For activity in whole cell lysates, cells
from overnight culture were harvested by centrifugation, washed twice in
PBS and resuspended in 1 × SDS-sample buffer. The mixture was then
placed in boiling water bath for 5 min. immediately prior to analysis by
SDS-PAGE as described above. For analysis of protease gene expression,
RNA was isolated using Direct-zolTM RNA miniprep kit (Zymo research) per
the manufacture’s protocol. Reverse transcription, RT-PCR were performed
using the primers listed in Table S2 as previously described.63 Relative
transcript abundance was determined by the –ΔΔCT, method normalized
to 16 s rRNA expression and relative to wild type as described.63 Unless
otherwise indicated, activities were measured following overnight culture.

Analysis of Fg processing and ﬂow cytometry
For analysis of Fg cleavage, culture supernatants were collected following
overnight culture and were clariﬁed by centrifugation and sterilized by
ﬁltration. Bovine Fg (Sigma-Aldrich) was then added to a ﬁnal concentration of 1 mg/ml and the mixture incubated at 37 °C for the time periods
designated in the text. Samples were then mixed with an equal volume of
2 × SDS-sample buffer and subjected to analysis by SDS-PAGE. Digestion
patterns were then assessed by staining with Coomassie Brilliant Blue R by
standard methods. For analysis of Fg-cell interaction by ﬂow cytometry,
strains were cultured overnight in optimized M9 medium or urine, each
supplemented with Alexa-Fluor 488 labeled human Fg (Thermo-Fisher
Scientiﬁc, F13191) at a ﬁnal concentration of 10 ng/ml. Bacterial samples
were analyzed directly from culture. Bacterial cells were counterstained
with SYTO®59 red ﬂuorescent nucleic acid stain (Thermo-Fisher Scientiﬁc,
S11341) (5 μM) 10 min. prior to ﬂow cytometry and the amount of Fg
associated with the cells was determined using a FACSCalibur ﬂow
cytometer (BD Biosciences) with analysis using FlowJo software (FlowJo,
LLC).

Statistical analyses
Data from multiple experiments were pooled. For experiments involving
infection, each strain was tested in a group of 5 mice, with independent
repetitions. The difference between WT and each mutant strain was tested
for signiﬁcance using a two-tailed Mann–Whitney U test. For other
experiments, data are derived from at least 3 independent experiments,
with values presented representing the mean ± SEM for each group with
differences tested for signiﬁcance using a paired t-test. Values below the
limit of detection (LOD) for CFU assays were assigned the LOD value (40
CFU). All statistical tests were performed using GraphPad Prism software
(ver. 5, GraphPad Software). For all statistical tests, the null hypothesis was
rejected for p < 0.05. In Figures, p values for speciﬁc comparisons were
indicated using the following symbols: <0.05 (*), <0.005 (**), and <0.001
(***).

Study approval
Urine samples were collected as per the study approval from the
Washington University School of Medicine Internal Review Board (approval
ID #201207143). All procedures involving animals were reviewed and
approved the Animal Studies Committee of the Washington University
School of Medicine.

Data availability
All data that support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
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Mouse catheter implantation, infection, and treatment

ADDITIONAL INFORMATION

Mice used in this study were six-week-old female wild-type C57BL/6Ncr
mice purchased from Charles Rivers Laboratories that were transurethrally
implanted with a 5-mm length of platinum-cured silicone catheter as
previously described.14 Animal chosen were randomized. Where indicated,
mice were transurethrally infected immediately after implantation with a
dose of ~2 × 107 CFU in PBS in a total volume of 50 µl. Mock infected mice
received 50 µl of PBS alone. For protease inhibitor therapy, tablets of the
inhibitor (cOmplete™ Mini, catalog #11836153001, Roche) were dissolved
in PBS according to the Manufacturer’s recommendations to achieve the
concentration stated in the text. Mice received intraperitoneal injections of
100 ul of the inhibitor solution, PBS alone (mock) and were implanted and
infected according to the schedule described in Fig. 5c. Urine was collected
at the designated time points (Fig. 5c) for analysis of Fg cleavage as
described above and bacterial titers in the catheter, kidney or bladder were
determined as previously described.7 Other inhibitors are described in
Fig. 6. Mice loss implanted catheters were excluded from data analysis.

Supplementary information accompanies the paper on the npj Bioﬁlms and
Microbiomes website (https://doi.org/10.1038/s41522-017-0036-z).

Histological analyses, microscopy and image processing
For histological analyses, bladders were ﬁxed in 10% formalin for 24 h and
dehydrated in 70% ethanol overnight at 4 °C. They were then embedded in
parafﬁn, sectioned, and stained with Hematoxylin and Eosin (H&E) for light
microscopy. Images were acquired using Leica DM1000 microscope
equipped with an EC3 digital camera. The histological images presented
were stitched together from multiple overlapping images using the
Photomerge function of Adobe Illustrator CC (ver. 2017.1.0) or LAS EZ
software (Leica Microsystems). For publication, images were processed
using Adobe Photoshop CC (ver. 2017.1.1) and prepared using Adobe
Illustrator CC (ver. 2017.1.0).
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